Thoughts on this? >> Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #productmarketing #biotech
LucidQuest’s Post
More Relevant Posts
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare
Roche was in 'advanced' talks to out-license its Angelman syndrome drug, but potential partner withdrew
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
EMD Serono lays out MS therapies' immune-system suppression risks in new campaign >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing
EMD Serono lays out MS therapies' immune-system suppression risks in new campaign
https://endpts.com
-
💊 Against the backdrop of the ongoing opioid crisis in the U.S., there exists a substantial and unmet need for potent, non-addictive painkillers. Enter Vertex and its promising first-in-class non-opioid candidate, suzetrigine. 🕵️♂️ Here are its recent milestones: 🌐 Head over to my pharma app for further drug analyses! https://lnkd.in/dVGQ6-8S
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Amgen’s MariTide to be tested in multiple obesity-related indications at PhIII >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #biotech #healthcare
As obesity market heats up, Amgen leaves clues on MariTide’s path forward
https://endpts.com
-
Thoughts on this? >> Akero returns with more MASH data to back PhIII FGF21 analog drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #productmarketing #biotech #pharma
Akero returns with more MASH data to back PhIII drug, touts fibrosis response rate
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Akero returns with more MASH data to back PhIII FGF21 analog drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #pharmaceutical #productmarketing
Akero returns with more MASH data to back PhIII drug, touts fibrosis response rate
https://endpts.com
-
Immunovant plans multiple trials for FcRn inhibitor based on PhI data to compete with argenx, J&J >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #productmarketing #pharmaceutical
Immunovant takes on argenx, J&J with plans to test FcRn inhibitor in multiple parallel trials after PhI win
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Immunovant plans multiple trials for FcRn inhibitor based on PhI data to compete with argenx, J&J >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #biotech #pharmaceutical
Immunovant takes on argenx, J&J with plans to test FcRn inhibitor in multiple parallel trials after PhI win
https://endpts.com
-
Thoughts on this? >> Crinetics reports second PhIII win for acromegaly drug, eyes 2025 launch >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #biotech #pharma
Crinetics reports second PhIII win for acromegaly drug, eyes 2025 launch
https://endpts.com
-
Thoughts on this? >> NS Pharma's Duchenne muscular dystrophy drug Viltepso flunks Phase 3 confirmatory trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #healthcare #biotech
Duchenne muscular dystrophy drug flunks Phase 3 confirmatory trial
endpts.com
